BioCentury
ARTICLE | Company News

Atomwise, Charles River partnership brings CRO model to AI

January 12, 2019 12:45 AM UTC

Atomwise Inc. (San Francisco, Calif.) is scaling up delivery of its artificial intelligence-based medicinal chemistry technology through a partnership with Charles River Laboratories International Inc. (NYSE:CRL) announced Friday. The alliance gives drug developers a CRO access point for AI technologies, circumventing the need for individual deals, and provides Atomwise with additional streams of revenue and data to feed its platform.

Through the partnership, Charles River customers can pay to use Atomwise's AtomNet platform for in silico hit discovery, lead optimization and off-target toxicity screening. The platform uses neural networks to infer chemistry principles from large data sets, and applies those principles to predict interactions between protein targets and small molecules...